Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: Results of a phase II study

Clinical and Translational Oncology

Volumn 9, Issue 5, 2007, Pages 317-322

  Estevez L G ^a,d   Sanchez Rovira P ^b   Domine M ^a   Leon A ^a   Calvo, I ^a   Jaen A ^b   Casado, V ^a   Rubio, G ^a   Diaz M ^a   Miro C ^a   Lobo, F ^a   Carrasco, E ^c   Casillas, M ^c   San Antonio, B ^c  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b Hosp Univ Ciudad de Jaén   (Spain)

^c ELI LILLY AND COMPANY   (Spain)

^d FiHM Centro Integral Oncológico Hospital de Madrid Clara Campal   (Spain)

Author keywords

Breast cancer; Docetaxel; Gemcitabine; Preoperative treatment

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; TAXOID;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; AXILLARY LYMPH NODE; BLEEDING; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LACRIMATION DISORDER; LEUKOPENIA; LIVER TOXICITY; LYMPH NODE DISSECTION; MASTECTOMY; MASTITIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROTOXICITY; PARTIAL MASTECTOMY; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; TAXOIDS;

EID: 34848826289     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0059-7     Document Type: Article

References (39)

1. De Lena M, Zucali R, Viganotti G et al (1978) Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1:53-59
2. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 97:188-194
3. Van de Vijver MJ, He YD, van't Verr LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
4. Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685
5. Wolmark N, Wang J, Mamounas E et al (2001) Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr (30): 96-102
6. Chollet P, Amat S, Cure H et al (2002) Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86:1041-1046
7. Bonadonna G, Valagussa P, Brambilla C et al (1998) Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100
8. Chan S, Friedrichs K, Noel D et al (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354
9. Nabholtz JM, Falkson C, Campos D et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975
10. Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313
11. Estevez LG, Cuevas JM, Antón A et al (2003) Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: Efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 9:686-692
12. Gradishar WJ (1997) Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology (Huntingt) 11[8 Suppl 8]: 15-18
13. Smith IC, Heys SD, Hutcheon AW et al (2002) Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466
14. Bear HD, Anderson S, Brown A et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174
15. Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027
16. Carmichael J, Possinger K, Phillip P et al (1995) Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 13:2731-2736
17. Perez-Manga G, Lluch A, Alba E et al (2000) Gemcitabine in combination with doxorubicin in advanced breast cancer: Final results of a phase II pharmacokinetic trial. J Clin Oncol 18:2545-2552
18. Colomer R, Llombart A, Lluch A et al (2000) Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: Preliminary results of a phase II trial. Semin Oncol 27[1 Suppl 2]:20-24
19. Gomez H, Kahatt C, Falcon S et al (2001) A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: A preliminary report. Semin Oncol 28[3 Suppl 10]:57-61
20. Sanchez-Rovira P, Jaen A, Dueñas R et al (2002) Neoadjuvant gemcitabine therapy for breast cancer [review]. Clin Breast Cancer 3[Suppl 1]:39-44
21. Alexopoulos A, Tryfonopoulos D, Karamouzis MV et al (2004) Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol 15: 95-99
22. Mavroudis D, Malamos N, Alexopoulos A et al (1999) Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol 10:211-215
23. Fountzilas G, Nicolaides C, Bafaloukos D et al (2000) Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A Hellenic Cooperative Oncology Group phase II study. Cancer Invest 18:503-509
24. Laufman LR, Spiridonidis CH, Pritchard J et al (2001) Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial. Ann Oncol 12:1259-1264
25. Lenz F, Beldermann F, Geberth M et al (2003) A phase II study of first-line combination chemotherapy with docetaxel and gemcitabine in anthracycline-pretreated, Her2-negative metastatic breast cancer (MBC) [abstract]. Eur J Cancer 1: S139 (abstr 455)
26. Kornek GV, Haider K, Kwasny W et al (2002) Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 8:1051-1056
27. Brandi M, Vici P, Lopez M et al and the Grupo Oncologico Italia Meridionale (2004) Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: Results of a multicenter phase II study. Semin Oncol 31[2 Suppl 5]:13-19
28. Slee PH, Jong PC, Jong RS et al (2005) Combination chemotherapy with docetaxel and gemcitabine in anthracycline pretreated patients with metastatic breast cancer (MBC) [abstract]. J Clin Oncol 23[16S, Part I]: 60s (abstr 728)
29. Pelegri A, Calvo L, Anton A et al and the Spanish Group for Breast Cancer Research GEICAM) (2005) Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: Final results of a phase II trial. Clin Breast Cancer 6:433-438 433-438
30. Palmeri S, Vaglica M, Spada S et al (2005) Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study [review]. Oncology 68:438-445
31. Mavroudis D, Malamos N, Polyzos A et al and the Breast Cancer Study Group of the Hellenic Oncology Research Group (HORG) (2004) Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: A multicenter phase II study. Oncology 67:250-256
32. Norton L (1999) Adjuvant breast cancer therapy: Current status and future strategies - growth kinetics and the improved drug therapy of breast cancer [review]. Semin Oncol 26[1 Suppl 3]:1-4
33. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
34. National Cancer Institute, Cancer Therapy Evaluation Program(CTEP) Reporting Guidelines [database on the internet]. Common Toxicity Criteria, Version 2.0 [published 1999 April 30; cited 2005 Nov 15]. Available from: http://ctep.cancer.gov/reporting/CTC-3test.html
35. Gianni L, Baselga L, Eiermann W et al (2005) European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF) [abstract]. J Clin Oncol 23[16S, Part I]: 7s (abstr 513)
36. Kuerer HM, Newman LA, Smith TL et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469
37. Valero V, Buzdar AU, Kau S-W et al (2002) Pathologically involved axillary nodes following primary chemotherapy (PCT) in locally advanced breast cancer (LABC) is an early biological prognostic factor of long-term outcome in patients with LABC: The University of Texas MD Anderson Cancer Center experience [abstract]. Ann Oncol 13[Suppl 5]: 37 (abstr 132P)
38. Thomas E, Holmes FA, Smith TL et al (2004) The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial. J Clin Oncol 22:2294-2302
39. Buzdar AU, Singletary SE, Valero V et al (2002) Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073-1079